- Details
- Alicia Morgans, MD, MPH, and Petros Grivas, MD, PhD, discuss the recent updates in the metastatic urothelial carcinoma (mUC) disease space. Together they discuss multiple presentations given during the virtual ASCO 2020 including the IMvigor010 trial. They discuss other adjuvant immunotherapy trials for mUC, as well as new results from IMvigor130 assessing biomarkers. Dr. Morgans and Dr. Grivas al...
|
- Details
- Cora Sternberg, MD, FACP, an investigator on the phase 3 JAVELIN Bladder 100 trial shares the study design, rationale, and key outcomes from the trial. The JAVELIN Bladder 100 trial is a phase 3 randomized study for maintenance avelumab therapy in patients who derived disease response or stabilization from first-line platinum-based chemotherapy for advanced urothelial cancer. In this conversation...
|
- Details
- The phase III JAVELIN Bladder 100 trial was the first urothelial carcinoma plenary session at an ASCO annual meeting in the meeting's history and Thomas Powles lead principal investigator on the trial along with Matthew Galsky join Alicia Morgans sharing results of this trial. This was a maintenance trial where first-line treatment with avelumab extended the survival over best supportive care (BSC...
|
- Details
- Joining Alicia Morgans at ASCO GU is Arjun Balar, a bladder cancer expert at New York University, who speaks to the most recent clinical trials and the future direction of available regimens regarding bladder preservation protocols. For the past 30 years, muscle-invasive urothelial cancer patients have been given two options for treatment: radical cystectomy or cisplatinum. With the more recent av...
|
- Details
- Srikala (Kala) Sridhar joins Alicia Morgans to discuss the recent developments in urothelial cancer of the bladder and upper tract. The two discuss controversial issues in urothelial carcinoma from the American Joint Committee on Cancer (AJCC) staging to chemotherapy in upper tract disease, to bladder sparing recent clinical trial findings, and the impact of those trials on clinical practice treat...
|
- Details
- Andrea Necchi, a medical oncologist and Ewan Gibb a researcher at Decipher Biosciences joins Alicia Morgans as they discuss new findings related to bladder cancer and the impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer, an area of unmet need in bladder cancer. The trio cover patient sel...
|
- Details
- Cora Sternberg joins Alicia Morgans at ASCO GU 2020 and discusses the significant advancements in the treatment of advanced bladder cancer looking back over the last 30 years. MVAC was regulatory approved as the first line treatment in metastatic bladder cancer thirty years ago. Cora discusses the recent progress that is offering significant improvements in the overall survival for those patients...
|
- Details
- Alicia Morgans is joined by Peter O’Donnell and Jonathan Rosenberg to discuss enfortumab vedotin (EV). This offers a new mechanism of action and is the first antibody-drug conjugate (ADC). This represents a targeted therapy and was studied in metastatic urothelial carcinoma. In reviewing the clinical data and side effects of the drug, the three clinicians highlight the effectiveness and tolerabili...
|
- Details
- Ashish Kamat sits down with Petros Grivas to discuss the recent advances and clinical trials in second and third-line therapies in metastatic urothelial cancer. Biographies: Petros Grivas, MD, PhD , Associate Professor, Clinical Director of Genitourinary Cancers Program, University of Washington, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center Ashish Kamat, MD,...
|
- Details
- In this conversation, Ronac Mamtani and Ravi Parikh join Alicia Morgans to discuss their recent work on bladder cancer outcomes and effectiveness research. They discuss immune checkpoint therapy versus carboplatin chemotherapy in patients with metastatic urothelial cancer (mUC). They also discuss the "Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cance...
|
